Liver Fibrosis - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 166 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Liver Fibrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H2 2014', provides an overview of the Liver Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Liver Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Liver Fibrosis Overview 8
Therapeutics Development 9
Pipeline Products for Liver Fibrosis - Overview 9
Pipeline Products for Liver Fibrosis - Comparative Analysis 10
Liver Fibrosis - Therapeutics under Development by Companies 11
Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes 14
Liver Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Liver Fibrosis - Products under Development by Companies 18
Liver Fibrosis - Products under Investigation by Universities/Institutes 21
Liver Fibrosis - Companies Involved in Therapeutics Development 22
ACROVIS biostructures GmbH 22
Advinus Therapeutics Ltd. 23
Angion Biomedica Corp. 24
BiOrion Technologies B.V. 25
Celgene Corporation 26
Digna Biotech, S.L. 27
FibroGen, Inc. 28
Galectin Therapeutics, Inc. 29
Genfit SA 30
GenKyoTex S.A. 31
Gilead Sciences, Inc. 32
GNI Group Ltd. 33
La Jolla Pharmaceutical Company 34
LG Life Sciences, Ltd. 35
Nitto Denko Corporation 36
Pfizer Inc. 37
Pharmaxis Limited 38
Promedior, Inc. 39
Promethera Biosciences S.A. 40
ProMetic Life Sciences Inc. 41
RXi Pharmaceuticals Corporation 42
Silence Therapeutics plc 43
TCM Biotech International Corp 44
Virobay Inc. 45
Liver Fibrosis - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
AbyD-3263 - Drug Profile 57
ANG-3281 - Drug Profile 58
ANG-3298 - Drug Profile 59
ANG-4011 - Drug Profile 60
BOT-162 - Drug Profile 61
BOT-191 - Drug Profile 62
CC-539 - Drug Profile 63
CC-90001 - Drug Profile 64
CIGB-500 - Drug Profile 65
CT-140 - Drug Profile 66
DB-036 - Drug Profile 67
disitertide - Drug Profile 68
Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis - Drug Profile 70
F-351 - Drug Profile 71
FG-3019 - Drug Profile 73
GCS-100 - Drug Profile 75
GFT-505 - Drug Profile 77
GKT-137831 - Drug Profile 80
GM-CT-01 - Drug Profile 81
GM-CT-02 - Drug Profile 84
GR-MD-01 - Drug Profile 85
GR-MD-02 - Drug Profile 87
HepaStem - Drug Profile 89
KBP-7018 - Drug Profile 91
KW-0 - Drug Profile 92
LC-280126 - Drug Profile 93
LJPC-201 - Drug Profile 95
melittin - Drug Profile 96
ND-L02s0201 - Drug Profile 97
NPLC-0393 - Drug Profile 99
P-17 - Drug Profile 100
PBI-4050 - Drug Profile 102
PRI-724 - Drug Profile 103
PRM-151 - Drug Profile 105
PXS-4728A - Drug Profile 107
PXS-5033-A - Drug Profile 108
RNAi Oligonucleotide for Hepatocellular Carcinoma, Ischemia Reperfusion Injury and Fulminant Fibrosis - Drug Profile 109
RXI-209 - Drug Profile 110
simtuzumab - Drug Profile 111
Small Molecule for Liver Fibrosis - Drug Profile 113
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 114
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 115
Small Molecules for Liver Diseases - Drug Profile 116
Small Molecules to Inhibit EGFR for Gastrointestinal Disorders - Drug Profile 117
Stem Cell Therapy for Liver Fibrosis and Liver Diseases - Drug Profile 118
Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology - Drug Profile 119
TCM-808FB - Drug Profile 120
TGFTX-4 Program - Drug Profile 121
VBY-376 - Drug Profile 122
VBY-825 - Drug Profile 123
Liver Fibrosis - Recent Pipeline Updates 124
Liver Fibrosis - Dormant Projects 153
Liver Fibrosis - Discontinued Products 154
Liver Fibrosis - Product Development Milestones 155
Featured News & Press Releases 155
Appendix 162
Methodology 162
Coverage 162
Secondary Research 162
Primary Research 162
Expert Panel Validation 162
Contact Us 163
Disclaimer 163

List of Tables
Number of Products under Development for Liver Fibrosis, H2 2014 12
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Development by Companies, H2 2014 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Liver Fibrosis - Pipeline by ACROVIS biostructures GmbH, H2 2014 25
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd., H2 2014 26
Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2014 27
Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2014 28
Liver Fibrosis - Pipeline by Celgene Corporation, H2 2014 29
Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2014 30
Liver Fibrosis - Pipeline by FibroGen, Inc., H2 2014 31
Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 32
Liver Fibrosis - Pipeline by Genfit SA, H2 2014 33
Liver Fibrosis - Pipeline by GenKyoTex S.A., H2 2014 34
Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2014 35
Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2014 36
Liver Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H2 2014 37
Liver Fibrosis - Pipeline by LG Life Sciences, Ltd., H2 2014 38
Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2014 39
Liver Fibrosis - Pipeline by Pfizer Inc., H2 2014 40
Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2014 41
Liver Fibrosis - Pipeline by Promedior, Inc., H2 2014 42
Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2014 43
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2014 44
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 45
Liver Fibrosis - Pipeline by Silence Therapeutics plc, H2 2014 46
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2014 47
Liver Fibrosis - Pipeline by Virobay Inc., H2 2014 48
Assessment by Monotherapy Products, H2 2014 49
Number of Products by Stage and Target, H2 2014 51
Number of Products by Stage and Mechanism of Action, H2 2014 54
Number of Products by Stage and Route of Administration, H2 2014 57
Number of Products by Stage and Molecule Type, H2 2014 59
Liver Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 127
Liver Fibrosis - Dormant Projects, H2 2014 156
Liver Fibrosis - Discontinued Products, H2 2014 157